Market Place
Sourcing Support
Inozyme Pharma to Present at Upcoming Investor Conferences
11 Nov 2024 //
GLOBENEWSWIRE
Inozyme Pharma Reports Q3 2024 Financial Results & Highlights
05 Nov 2024 //
GLOBENEWSWIRE
Inozyme Pharma Shares Positive Phase 1 SEAPORT 1 Data
24 Oct 2024 //
GLOBENEWSWIRE
Inozyme Presents Interim Data From Phase 1 Trial At ASN 2024
17 Oct 2024 //
GLOBENEWSWIRE
Inozyme Pharma Appoints Erik Harris To Board Of Directors
07 Oct 2024 //
GLOBENEWSWIRE
Inozyme Pharma Presents New Data At ASBMR 2024 Annual Meeting
26 Sep 2024 //
GLOBENEWSWIRE
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
29 Aug 2024 //
GLOBENEWSWIRE
Inozyme Pharma Reports Q2 2024 Results And Business Highlights
06 Aug 2024 //
GLOBENEWSWIRE
Inozyme Publishes Preclinical Data Supporting INZ-701 For Rare Diseases
25 Jul 2024 //
GLOBENEWSWIRE
Inozyme`s INZ-701 Receives FDA Fast Track For ABCC6 Deficiency
02 Jul 2024 //
GLOBENEWSWIRE
Inozyme ICCBH Sponsored Symposium Children`s Bone Health
21 Jun 2024 //
GLOBENEWSWIRE
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Inozyme Enpp1 Pxe Phase Trials: Inz-701 Medical Conference Data
23 May 2024 //
GLOBENEWSWIRE
Inozyme At BofA Securities Healthcare Conference 2024
08 May 2024 //
GLOBENEWSWIRE
Inozyme Pharma Reports Q1 2024 Financials And Business Highlights
07 May 2024 //
GLOBENEWSWIRE
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 May 2024 //
GLOBENEWSWIRE
Inozyme Announces Positive Data from Ph 1/2 Trials of INZ-701 in Adults
08 Apr 2024 //
GLOBENEWSWIRE
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Apr 2024 //
GLOBENEWSWIRE
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Conference
02 Apr 2024 //
GLOBENEWSWIRE
Inozyme to Report Data from Ongoing Phase 1/2 Trials of INZ-701
26 Mar 2024 //
GLOBENEWSWIRE
Inozyme Pharma Reports Full Year 2023 Financial Results
12 Mar 2024 //
GLOBENEWSWIRE
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
26 Feb 2024 //
GLOBENEWSWIRE
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Feb 2024 //
GLOBENEWSWIRE
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Dec 2023 //
GLOBENEWSWIRE
Inozyme Pharma to Participate in Upcoming Investor Conferences
09 Nov 2023 //
GLOBENEWSWIRE
Inozyme Pharma Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Nov 2023 //
GLOBENEWSWIRE
Inozyme Pharma Announces Presentation at the ASN Kidney Week 2023
26 Oct 2023 //
GLOBENEWSWIRE
Inozyme Highlights Inclusion of GACI in Genomics England™s Generation Study
10 Oct 2023 //
GLOBENEWSWIRE
Inozyme Pharma Announces Three Poster Presentations at ASBMR
06 Oct 2023 //
GLOBENEWSWIRE
Inozyme Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701
26 Sep 2023 //
GLOBENEWSWIRE
Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023
20 Sep 2023 //
GLOBENEWSWIRE
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Sep 2023 //
GLOBENEWSWIRE
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Conference
05 Sep 2023 //
GLOBENEWSWIRE
Inozyme Pharma Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Aug 2023 //
GLOBENEWSWIRE
Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock
01 Aug 2023 //
GLOBENEWSWIRE
Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock
27 Jul 2023 //
GLOBENEWSWIRE
Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock
27 Jul 2023 //
GLOBENEWSWIRE
Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701
26 Jul 2023 //
GLOBENEWSWIRE
Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023
19 Jul 2023 //
GLOBENEWSWIRE
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency
27 Jun 2023 //
GLOBENEWSWIRE
Inozyme Pharma to Present at the Jefferies Healthcare Conference
02 Jun 2023 //
GLOBENEWSWIRE
Inozyme Pharma Reports1Q 2023 FYR and Provides Business Highlights
09 May 2023 //
GLOBENEWSWIRE
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 May 2023 //
GLOBENEWSWIRE
Inozyme to Present Announced Data from Phase 1/2 Trial in ENPP1 Deficiency
14 Apr 2023 //
GLOBENEWSWIRE
Inozyme to Participate at the 22nd Annual Needham Virtual Healthcare Conference
11 Apr 2023 //
GLOBENEWSWIRE
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2023 //
GLOBENEWSWIRE
Inozyme Pharma Reports Full Year 2022 Financial Results
22 Mar 2023 //
GLOBENEWSWIRE
Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference
01 Mar 2023 //
GLOBENEWSWIRE
Inozyme Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701
16 Feb 2023 //
GLOBENEWSWIRE
Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023
06 Feb 2023 //
GLOBENEWSWIRE
Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress
09 Jan 2023 //
GLOBENEWSWIRE
Inozyme Pharma Announces Peer-Reviewed Publication Revealing Prevalence of ENPP1
05 Dec 2022 //
GLOBENEWSWIRE
Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
01 Dec 2022 //
GLOBENEWSWIRE
Inozyme Pharma Reports 3Q 2022 Financial Results and Provides Business Updates
10 Nov 2022 //
GLOBENEWSWIRE
Inozyme Pharma to Participate in Upcoming Investor Conferences
07 Nov 2022 //
GLOBENEWSWIRE
Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1
03 Nov 2022 //
GLOBENEWSWIRE
Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database
31 Oct 2022 //
GLOBENEWSWIRE
Inozyme Pharma to Present at H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
